Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rose bengal sodium - Provectus Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Rose bengal sodium - Provectus Biopharmaceuticals

Alternative Names: PH-10; Provecta; PV-10; Rose bengal; Rose bengal disodium; Rose bengal sodium I 125; Rose bengal sodium I 131; Xantryl

Latest Information Update: 28 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Photogen Technologies Inc.
  • Developer Pediatric Oncology Experimental Therapeutics Investigators Consortium; Provectus Biopharmaceuticals; University of Calgary
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials; Antineoplastics; Antipsoriatics; Antivirals; Benzoates; Eye disorder therapies; Fluoresceins; Halogenated hydrocarbons; Skin disorder therapies; Small molecules; Xanthenes
  • Mechanism of Action Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma; Liver cancer; Neuroblastoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Atopic dermatitis; Psoriasis
  • Phase I Actinic keratosis; Neuroendocrine tumours
  • Preclinical COVID 2019 infections; Ewing's sarcoma; Gram-negative infections; Gram-positive infections; Haematological malignancies; Infectious keratitis; Lymphoid leukaemia; Myeloid leukaemia; Osteosarcoma; Rhabdomyosarcoma; Solid tumours; Squamous cell cancer; Wounds
  • No development reported Liver cancer; Liver metastases; Pancreatic cancer
  • Discontinued Acne vulgaris; Breast cancer

Most Recent Events

  • 28 May 2024 Pharmacodynamics and safety data from preclinical studies in Wounds released by Provectus Biopharmaceuticals
  • 21 May 2024 Preclinical trials in Wounds in USA (Topical)
  • 02 May 2024 Provectus Biopharmaceuticals receives patent allowance for Rose bengal sodium for Leukaemia in US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top